This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., USA.
Reference
Loong HH, et al. Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong. Cost Effectiveness and Resource Allocation : 15 Jan 2020. Available from: URL: https://doi.org/10.1186/s12962-020-0200-9
Rights and permissions
About this article
Cite this article
Pembrolizumab good value in advanced melanoma in Hong Kong. PharmacoEcon Outcomes News 845, 24 (2020). https://doi.org/10.1007/s40274-020-6527-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6527-9